These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

266 related articles for article (PubMed ID: 33965340)

  • 1. Botulinum toxin in the management of primary and secondary Raynaud's phenomenon.
    Ennis D; Ahmad Z; Anderson MA; Johnson SR
    Best Pract Res Clin Rheumatol; 2021 Sep; 35(3):101684. PubMed ID: 33965340
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Beneficial effect of botulinum toxin A on Raynaud's phenomenon in Japanese patients with systemic sclerosis: A prospective, case series study.
    Motegi S; Yamada K; Toki S; Uchiyama A; Kubota Y; Nakamura T; Ishikawa O
    J Dermatol; 2016 Jan; 43(1):56-62. PubMed ID: 26173902
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Botulinum toxin type A contribution in the treatment of Raynaud's phenomenon due to systemic sclerosis].
    Serri J; Legré R; Veit V; Guardia C; Gay AM
    Ann Chir Plast Esthet; 2013 Dec; 58(6):658-62. PubMed ID: 22204894
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Successful treatment of Raynaud's phenomenon and digital ulcers in systemic sclerosis patients with botulinum toxin B injection: Assessment of peripheral vascular disorder by angiography and dermoscopic image of nail fold capillary.
    Motegi SI; Sekiguchi A; Saito S; Ishibuchi H; Kishi C; Yasuda M; Ishikawa O
    J Dermatol; 2018 Mar; 45(3):349-352. PubMed ID: 29164658
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeted high concentration botulinum toxin A injections in patients with Raynaud's phenomenon: a retrospective single-centre experience.
    Nagarajan M; McArthur P
    Rheumatol Int; 2021 May; 41(5):943-949. PubMed ID: 32447423
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of Botulinum Toxin B Injection for Raynaud's Phenomenon and Digital Ulcers in Patients with Systemic Sclerosis.
    Motegi SI; Uehara A; Yamada K; Sekiguchi A; Fujiwara C; Toki S; Date Y; Nakamura T; Ishikawa O
    Acta Derm Venereol; 2017 Jul; 97(7):843-850. PubMed ID: 28358168
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Management of Raynaud's phenomenon and digital ischemia.
    Herrick AL
    Curr Rheumatol Rep; 2013 Jan; 15(1):303. PubMed ID: 23292819
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The efficacy of botulinum toxin A in the treatment of Raynaud's phenomenon in systemic sclerosis: A randomized self-controlled trial.
    Du W; Zhou M; Zhang C; Sun Q
    Dermatol Ther; 2022 Jul; 35(7):e15529. PubMed ID: 35441772
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Botulinum toxin injection for refractory Raynaud phenomenon and digital ulcers in systemic sclerosis.
    Shen YH; Lee YH; Leong PY
    Int J Rheum Dis; 2023 Feb; 26(2):187-189. PubMed ID: 36703271
    [No Abstract]   [Full Text] [Related]  

  • 10. Botulinum toxin for Raynaud's phenomenon associated with systemic sclerosis: comment on the article by Senet et al.
    Yin H; Liu B; Li Q; Yan Q; Lu L
    Arthritis Rheumatol; 2023 Mar; 75(3):486. PubMed ID: 36209513
    [No Abstract]   [Full Text] [Related]  

  • 11. Evaluation of Botulinum Toxin Type A and its Potential Effect on Exacerbated Raynaud's Phenomenon in Hospitalized Scleroderma Patients.
    Seyedmardani SM; Aghdashi MA; Soltani S; Zonouz GK
    Curr Rheumatol Rev; 2022; 18(1):48-57. PubMed ID: 34636314
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A prospective study of the use of botulinum toxin injections in the treatment of Raynaud's syndrome associated with scleroderma.
    Uppal L; Dhaliwal K; Butler PE
    J Hand Surg Eur Vol; 2014 Oct; 39(8):876-80. PubMed ID: 24369360
    [TBL] [Abstract][Full Text] [Related]  

  • 13. OnabotulinumtoxinA for Systemic Sclerosis-associated Raynaud's Phenomenon: A Multi-Institutional Study on Accessibility and Effectiveness.
    Kassamali B; Desai S; Min M; Mazori D; Villa-Ruiz C; Kus K; Cobos G; Merola J; LaChance A; Vleugels R
    J Drugs Dermatol; 2021 Nov; 20(11):1257-1259. PubMed ID: 34784129
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Statins: potentially useful in therapy of systemic sclerosis-related Raynaud's phenomenon and digital ulcers.
    Abou-Raya A; Abou-Raya S; Helmii M
    J Rheumatol; 2008 Sep; 35(9):1801-8. PubMed ID: 18709692
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Optimisation of botulinum toxin type a treatment for the management of Raynaud's phenomenon using a dorsal approach: a prospective case series.
    Dhaliwal K; Griffin MF; Salinas S; Howell K; Denton CP; Butler PEM
    Clin Rheumatol; 2019 Dec; 38(12):3669-3676. PubMed ID: 31482318
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The novel use of botulinum toxin A for the treatment of Raynaud's phenomenon in the toes.
    Dhaliwal K; Griffin M; Denton CP; Butler PEM
    BMJ Case Rep; 2018 Mar; 2018():. PubMed ID: 29525756
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ischemic ulcers of the toes secondary to Raynaud's phenomenon in a child successfully treated with botulinum toxin.
    Quintana Castanedo L; Feito Rodríguez M; Maseda Pedrero R; Chiloeches Fernández C; de Lucas Laguna R
    Pediatr Dermatol; 2020 Jul; 37(4):681-683. PubMed ID: 32212180
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and Safety of Botulinum Toxin in Adults with Raynaud's Phenomenon Secondary to Systemic Sclerosis: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study.
    Senet P; Maillard H; Diot E; Lazareth I; Blaise S; Arnault JP; Pistorius MA; Boulon C; Cogrel O; Warzocha U; Rivière S; Malloizel-Delaunay J; Servettaz A; Sassolas B; Viguier M; Monfort JB; Janique S; Vicaut E;
    Arthritis Rheumatol; 2023 Mar; 75(3):459-467. PubMed ID: 36066501
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Raynaud's phenomenon.
    Hughes M; Herrick AL
    Best Pract Res Clin Rheumatol; 2016 Feb; 30(1):112-32. PubMed ID: 27421220
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prospective, open-label, uncontrolled pilot study to study safety and efficacy of sildenafil in systemic sclerosis-related pulmonary artery hypertension and cutaneous vascular complications.
    Kumar U; Sankalp G; Sreenivas V; Kaur S; Misra D
    Rheumatol Int; 2013 Apr; 33(4):1047-52. PubMed ID: 22833239
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.